 Protagonist Therapeutics Inc NASDAQ: PTGX received a letter from the FDA indicating the agencys intent to rescind Breakthrough Therapy Designation for the companys rusfertide product candidate in polycythemia vera. Polycythemia vera is a type of blood cancer. 